Review anchor
Bifunctional purine biosynthesis protein ATIC
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Bifunctional purine biosynthesis protein ATIC
CHEMBL2518
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Bifunctional purine biosynthesis protein ATIC as ChEMBL target CHEMBL2518, mapped to UniProt P31939. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2518
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P31939
Bifunctional purine biosynthesis protein ATIC
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Bifunctional purine biosynthesis protein ATIC matters
Bifunctional purine biosynthesis protein ATIC is reviewed as Bifunctional purine biosynthesis protein ATIC (UniProt P31939); the current evidence base includes 3 approved drugs, 208 compounds, and 70 assays, with lead potency reaching pChEMBL 8.4.
Protein context
Bifunctional purine biosynthesis protein ATIC
Bifunctional purine biosynthesis protein ATIC Sequence length is 592 aa.
Review this target as Bifunctional purine biosynthesis protein ATIC, mapped to UniProt P31939. Sequence length is 592 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P31939
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 3 approved drugs, 208 compounds, and 70 assays for this target. The dominant activity type is IC50. CHEMBL4100363 is the current potency anchor at pChEMBL 8.4.
Use CHEMBL4100363 as the tractability anchor when discussing potency (pChEMBL 8.4).
Activity source · ChEMBL 36 via Core Engine
3 approved
pChEMBL 8.4
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Bifunctional purine biosynthesis protein ATIC matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P31939, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
208
Total Compounds
70
Total Assays
3
Approved Drugs
IC50: 66.0, KI: 61.0, EC50: 21.0, KD: 3.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4100363
|
8.4 | EC50 | — |
|
|
No preferred name
CHEMBL1231520
|
8.2 | Ki | — |
|
|
No preferred name
CHEMBL4063104
|
8.1 | EC50 | — |
|
|
No preferred name
CHEMBL4081385
|
8.1 | IC50 | — |
|
|
No preferred name
CHEMBL4081385
|
8.1 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
PEMETREXED
CHEMBL225072
|
2004 |
|
|
METHOTREXATE
CHEMBL34259
|
1953 |
Source Header